AU2019224003A1 - Compounds and compositions for the treatment of muscular disorders - Google Patents

Compounds and compositions for the treatment of muscular disorders Download PDF

Info

Publication number
AU2019224003A1
AU2019224003A1 AU2019224003A AU2019224003A AU2019224003A1 AU 2019224003 A1 AU2019224003 A1 AU 2019224003A1 AU 2019224003 A AU2019224003 A AU 2019224003A AU 2019224003 A AU2019224003 A AU 2019224003A AU 2019224003 A1 AU2019224003 A1 AU 2019224003A1
Authority
AU
Australia
Prior art keywords
epicatechin
bone
composition
muscle
weakness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019224003A
Other languages
English (en)
Inventor
Guillermo Ceballos
Sundeep Dugar
George F. Schreiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epirium Bio Inc
Original Assignee
Epirium Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/900,533 external-priority patent/US20180193306A1/en
Application filed by Epirium Bio Inc filed Critical Epirium Bio Inc
Publication of AU2019224003A1 publication Critical patent/AU2019224003A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019224003A 2018-02-20 2019-02-20 Compounds and compositions for the treatment of muscular disorders Pending AU2019224003A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/900,533 2018-02-20
US15/900,533 US20180193306A1 (en) 2012-03-23 2018-02-20 Compounds and compositions for the treatment of muscular disorders and bone disorders
PCT/US2019/018730 WO2019164914A1 (fr) 2018-02-20 2019-02-20 Composés et compositions pour le traitement de troubles musculaires

Publications (1)

Publication Number Publication Date
AU2019224003A1 true AU2019224003A1 (en) 2020-10-08

Family

ID=67687368

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019224003A Pending AU2019224003A1 (en) 2018-02-20 2019-02-20 Compounds and compositions for the treatment of muscular disorders

Country Status (8)

Country Link
EP (1) EP3755319A4 (fr)
JP (1) JP2021514380A (fr)
CN (1) CN111989098A (fr)
AU (1) AU2019224003A1 (fr)
BR (1) BR112020016923A2 (fr)
CA (1) CA3091892A1 (fr)
IL (1) IL276786A (fr)
WO (1) WO2019164914A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10052316B2 (en) 2011-06-06 2018-08-21 Cardero Therapeutics, Inc. Methods and compositions for treatment of mitochondrial toxicity
US10898465B2 (en) 2016-06-21 2021-01-26 Epirium Bio Inc. Utility of (+) epicatechin and their analogs
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
WO2024036225A1 (fr) * 2022-08-10 2024-02-15 Epirium Bio Inc. Épicatéchine pour l'inhibition de la toxicité du glutamate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572934A4 (fr) * 2002-02-21 2007-12-19 Wyeth Corp Domaine follistatine contenant des proteines
JP2004161669A (ja) * 2002-11-13 2004-06-10 Ito En Ltd 骨形成促進剤
CN100361655C (zh) * 2005-09-05 2008-01-16 中山大学 (-)-表没食子儿茶素没食子酸酯-钙络合物固体分散体及其制备方法与应用
CA2690685A1 (fr) * 2007-06-20 2008-12-24 Galapagos N.V. Cibles et composes moleculaires utiles dans le traitement de maladies degeneratives des os et des articulations, et procedes pour les identifier
KR101760758B1 (ko) * 2008-05-14 2017-07-24 애그리컬쳐 빅토리아 서비스 피티와이 엘티디 질병 및 장애를 치료하기 위한 안지오게닌 또는 안지오게닌 아고니스트의 이용
JP2010095474A (ja) * 2008-10-17 2010-04-30 Ito En Ltd カルシウム吸収促進組成物及びカルシウム吸収促進飲食物
KR101096574B1 (ko) * 2008-12-12 2011-12-20 에이치 엘 지노믹스(주) 유럽종 포도의 씨 추출물을 함유하는 골다공증 예방 또는 치료용 약학 조성물
JP2011006355A (ja) * 2009-06-25 2011-01-13 Ito En Ltd 骨密度改善組成物及び飲食物
JP2013051920A (ja) * 2011-09-05 2013-03-21 Ishikawa Prefectural Public Univ Corp 骨密度強化補助食品
WO2013142816A1 (fr) * 2012-03-23 2013-09-26 Cardero Therapeutics, Inc. Composés et compositions pour le traitement d'affections musculaires
CN107048383A (zh) * 2012-10-04 2017-08-18 雅培制药有限公司 用于增强EGCg对减缓骨骼肌损失的作用的方法
KR102078357B1 (ko) * 2014-06-16 2020-02-17 유니젠, 인크. 뼈 장애, 연골 장애, 또는 이 둘 다의 관리 또는 개선을 위한 조성물 및 방법

Also Published As

Publication number Publication date
WO2019164914A1 (fr) 2019-08-29
CA3091892A1 (fr) 2019-08-29
CN111989098A (zh) 2020-11-24
EP3755319A4 (fr) 2021-12-01
BR112020016923A2 (pt) 2020-12-15
EP3755319A1 (fr) 2020-12-30
IL276786A (en) 2020-10-29
JP2021514380A (ja) 2021-06-10

Similar Documents

Publication Publication Date Title
US9901564B2 (en) Compounds and compositions for the treatment of muscular disorders
US11273144B2 (en) Compounds and compositions for the treatment of muscular disorders and bone disorders
US20220105117A1 (en) Compositions comprising nicotinamide riboside and a urolithin
EP3755319A1 (fr) Composés et compositions pour le traitement de troubles musculaires
AU2006227949B2 (en) Composition and method for modulating hydrogen ion physiology
AU2007275561B2 (en) Improvement of arginase levels/activity
US11464753B2 (en) Composition for treatment of neurodegenerative disease
KR20100094485A (ko) 아미노산 조성물을 함유하는 피로 방지제
US20230255238A2 (en) Compositions and methods using at least one of oleuropein or a metabolite thereof to treat or prevent muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise
WO2020127183A1 (fr) Nouveaux composés de polyméthoxyflavone pour la modulation du muscle squelettique, procédés et utilisations de ceux-ci
JP7271016B2 (ja) 骨損失疾患の予防、改善または治療のためのｃｈｐ（シクロ－ヒスプロ）および副甲状腺ホルモンを含む組成物の用途
CN116075304A (zh) 含有烟酰胺和维生素b6的组合物以及使用此类组合物来治疗肌肉减少症和虚弱的方法